Ketorolac tromethamine

Base Information

• Chemical Name: Ketorolac tromethamine
• CAS No.: 74103-07-4
• Molecular Formula: C15H13NO3
• Molecular Weight: 376.40
• Hs Code.: 2933995500
• European Community (EC) Number: 620-545-3
• NSC Number: 758637
• UNII: 4EVE5946BQ
• DSSTox Substance ID: DTXSID0045597
• Wikidata: Q27107089
• NCI Thesaurus Code: C61798
• RXCUI: 28200
• Pharos Ligand ID: WFQSSV4W94CL
• ChEMBL ID: CHEMBL1201124
• Mol file: 74103-07-4.mol

Synonyms:Acular;Ketorolac Tromethamine;Toradol

Chemical Property of Ketorolac tromethamine

Chemical Property:

• Appearance/Colour: crystalline
• Melting Point: 160-161 °C
• Boiling Point: 493.2 °C at 760 mmHg
• Flash Point: 252.1 °C
• PSA: 146.01000
• LogP: 0.65210
• Storage Temp.: Hygroscopic, Refrigerator, Under Inert Atmosphere
• Solubility.: H2O: 15 mg/mL stable at least one month at −20
• Hydrogen Bond Donor Count: 5
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 6
• Exact Mass: 376.16343649
• Heavy Atom Count: 27
• Complexity: 430

Purity/Quality:

99% ^*data from raw suppliers

rac Ketorolac Tromethamine Salt| ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T
• Hazard Codes: T
• Statements: 25-36/37/38-23/24/25
• Safety Statements: 26-45-36/37/39

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O.C(C(CO)(CO)N)O
• Recent ClinicalTrials: NSAIDs Stent Study
• Recent EU Clinical Trials: Low dose versus normal dose ketorolac for postoperative pain after prostatectomy and hysterectomy: a Double-blind Randomized Controlled Non-inferiority Trial
• Description: Ketorolac tromethamine is a nonsteroidal antiinflammatory agent that exhibits analgesic and antipyretic activity. The compound is effective in the management of moderate to severe postoperative pain. It is, however, the first of this type of agent to be administered parenterally as an analgesic and is specifically indicated for intramuscular injection. Ketorolac represents a useful alternative to the narcotic analgesics due to its lack of abuse potential. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) and a non-selective COX inhibitor (IC50 = 20 nM for both COX-1 and COX-2). It prevents increases in paw swelling, increases paw withdrawal latency in a hot-plate test, and decreases prostaglandin E2 (PGE2) levels in paw tissue in a mouse model of carrageenan-induced inflammation when administered at a dose of 30 mg/kg. Ketorolac is a racemic mixture containing the active (S)-ketorolac and inactive (R)-ketorolac enantiomers. Formulations containing ketorolac have been used to manage postoperative pain and as ophthalmic solutions to treat ocular pain and inflammation.
• Uses: Analgesic;Cyclooxygenase Inhibitor Ketorolac is used primarily for its analgesic effects for short-term treatment of mild to moderate pain in dogs and rodents. The duration of analgesic effect in dogs is about 8 – 12 hours, but because of the availability of approved, safer NSAIDs for dogs, its use is questionable.
• Indications: Ketorolac tromethamine is a pyrrolol-pyrrole nonsteroidal anti- inflammatory agent that inhibits prostaglandin formation. Prostaglandins mediate inflammation within the eye by disrupting the blood-aqueous barrier, inducing vasodilation and increasing intraocular pressure. Prostaglandins may also cause iris sphincter constriction (miosis) independent of cholinergic mechanisms. Ketorolac tromethamine is marketed for use before cataract extraction in human patients (to prevent miosis during surgery) and for control of post surgical inflammation, especially following cataract surgery. It is also approved for management of conjunctivitis associated with seasonal allergy in people. In veterinary medicine, ketorolac tromethamine is primarily used to control surgical or nonsurgical uveitis particularly in cases with concurrent corneal bacterial infection or ulceration when topical corticosteroids are contraindicated. It is also used in diabetic patients, especially smaller patients, adversely affected by systemic uptake of topically applied corticosteroids. Nonsteroidal agents like ketorolac tromethamine can be combined with topical steroids in patients with severe uveal inflammation.